Hemab Therapeutics (NASDAQ:COAG) Shares Down 3.8% – Should You Sell?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s share price dropped 3.8% during trading on Wednesday . The stock traded as low as $40.52 and last traded at $41.67. Approximately 7,464 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 268,744 shares. The stock had previously closed at $43.31.

Wall Street Analysts Forecast Growth

COAG has been the topic of several recent analyst reports. Wedbush reissued an “outperform” rating and set a $55.00 price target (up from $42.00) on shares of Hemab Therapeutics in a research report on Monday. Jefferies Financial Group raised their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday. Evercore assumed coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price on the stock. HC Wainwright upped their target price on Hemab Therapeutics from $40.00 to $52.00 and gave the company a “buy” rating in a report on Monday. Finally, The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Hemab Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.00.

Hemab Therapeutics Trading Up 2.8%

The company’s 50 day moving average is $29.73. The stock has a market capitalization of $2.08 billion and a price-to-earnings ratio of -1.86.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Insider Activity at Hemab Therapeutics

In other Hemab Therapeutics news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the acquisition, the director owned 6,149,096 shares of the company’s stock, valued at $110,683,728. This trade represents a 77.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have acquired 2,970,541 shares of company stock worth $55,459,603.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.